Medical Devices & Equipment

Chiba Plant

Responding to the needs of the medical field as a surgical suture manufacturer

Our NESCOSUTURE® is manufactured according to international standards and is receiving support from doctors and nurses in the surgery, cardiovascular surgery, etc., and plastic surgery departments of hospitals and core facilities around the country. In addition, we have a rich product lineup of over 2,000 items, and we have developed synthetic absorbable sutures under the brand name “Opepolyx®,” which achieves an equivalent operability to braided silk (or silk sutures) that are considered the easiest to use. We also meet the needs of the medical field by developing and selling products with excellent operability, such as black-colored suture needles.

Development of surgical equipment with one-of-a-kind technology developed over many years

Alfresa Pharma is the first domestic manufacturer of microwave surgical equipment: the Microtaze® —a microwave endometrial ablation device used for menorrhagia that is being recognized for reducing the burden on the patient. As of April 1, 2012, it became covered by insurance and available to more patients.

Providing surgical materials and instruments that enhance intraoperative and postoperative safety

The NESPLON® Cable System, a cable system for intracorporeal fixation, is widely used in orthopedic surgery as a wiring material for bone fixation, contributing to intraoperative and postoperative safety.
We have also developed the “TIGHTING GUN,” a specialized surgical instrument required for fastening, contributing to safe and appropriate surgery.

Medical devices from Japan that expand the possibilities of radiotherapy

NESKEEP® absorbable tissue spacer for radiotherapy is an absorbable spacer that enables treatment of patients who have difficulty undergoing radiotherapy due to organs at risk (OAR) in close proximity. We have developed, manufactured, and marketed absorbable spacers made in Japan through industry-academia collaboration. We will contribute to the improvement of QOL by providing treatment opportunities to patients who have been unable to receive adequate radiotherapy.